Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 8 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
Kowa Company, Ltd. is currently managing 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 7 distinct examiners, which indicates a highly decentralized review process where each case is handled by a different official. This variety of perspectives is also reflected in the organizational structure, as the actions are spread across 6 distinct art units. This suggests that the company's biotechnology innovations are being evaluated by a wide range of specialized groups within the patent office. Prosecution in this area often faces rigorous scrutiny regarding enablement and written description.
The busiest examiner, ROSENTHAL, ANDREW S, is currently responsible for 1 pending office action. Given that there are 7 pending office actions in total, the workload is spread very thinly, with each of the 7 distinct examiners managing only one case. For the legal team, this requires a strategy that can adapt to seven different examiner styles while maintaining consistency across the 6 distinct art units. The fact that each examiner, including the busiest, handles only 1 pending office action ensures that no single individual has a disproportionate impact on the portfolio. This decentralized structure requires a coordinated approach to managing these active matters.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (22%) |
| §103 only | 4 (44%) |
| §102 only | 1 (11%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSENTHAL, ANDREW S | 1 | 51.9% | +39.0% |
| KENYON, JOHN S | 1 | 79.7% | +18.2% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| DRAPER, LESLIE A ROYDS | 1 | 27.3% | +43.4% |
| CHENG, KAREN | 1 | 76.4% | +26.6% |
| APENTENG, JESSICA MCMILLAN | 1 | 65.3% | +18.8% |
| MANDEVILLE, JASON M | 1 | 55.5% | +46.3% |
| RYAN, DOUGLAS CHARLES | 1 | 38.2% | +48.4% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611949 | MASS PRODUCTION SYSTEM OF RECOMBINANT BAGWORM SILK THREAD PROTEIN | RYAN, DOUGLAS CHARLES | 17d overdue |
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | DRAPER, LESLIE A ROYDS | 14d |
| 19101601 | POLYMER CONTRAST AGENT | ROSENTHAL, ANDREW S | — |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | ROZOF, TIMOTHY R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17611949 | MASS PRODUCTION SYSTEM OF RECOMBINANT BAGWORM SILK THREAD PROTEIN | RYAN, DOUGLAS CHARLES | 17d overdue |
| 18287210 | RING-TYPE LIGHTING DEVICE | APENTENG, JESSICA MCMILLAN | 4d overdue |
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | DRAPER, LESLIE A ROYDS | 14d |
| 19101601 | POLYMER CONTRAST AGENT | ROSENTHAL, ANDREW S | — |
| 18880136 | DRUG FOR LOWERING BLOOD LDL CHOLESTEROL | KENYON, JOHN S | — |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | ROZOF, TIMOTHY R | — |
| 18287809 | COMBINATION MEDICINE FOR PREVENTING/TREATING DYSLIPIDEMIA OR CARDIOVASCULAR DISEASE | CHENG, KAREN | — |
| 18043282 | MEDICAL EXAMINATION DEVICE | MANDEVILLE, JASON M | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1613 | 1 |
| 1625 | 1 |
| 1623 | 1 |
| 2875 | 1 |
| 2623 | 1 |
| 1635 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19101601 | POLYMER CONTRAST AGENT | ROSENTHAL, ANDREW S | 1613 | §102§112Other | Non-Final OA | — | Pending | Feb 06, 2025 |
| 18880136 | DRUG FOR LOWERING BLOOD LDL CHOLESTEROL | KENYON, JOHN S | 1629 | §102 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | ROZOF, TIMOTHY R | 1625 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | DRAPER, LESLIE A ROYDS | 1629 | §102§112Other | Non-Final OA | 14d | Pending | Mar 15, 2024 |
| 18287809 | COMBINATION MEDICINE FOR PREVENTING/TREATING DYSLIPIDEMIA OR CARDIOVASCULAR DISEASE | CHENG, KAREN | 1623 | §103 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18287210 | RING-TYPE LIGHTING DEVICE | APENTENG, JESSICA MCMILLAN | 2875 | §103 | Non-Final OA | 4d overdue | Pending | Oct 17, 2023 |
| 18043282 | MEDICAL EXAMINATION DEVICE | MANDEVILLE, JASON M | 2623 | §103 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 17611949 | MASS PRODUCTION SYSTEM OF RECOMBINANT BAGWORM SILK THREAD PROTEIN | RYAN, DOUGLAS CHARLES | 1635 | §101§102§103 | Non-Final OA | 17d overdue | Pending | Nov 17, 2021 |
| 14903114 | DRUG FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE | BARSKY, JARED | 1628 | §103 | Non-Final OA | — | Pending | Jan 06, 2016 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKowa Company, Ltd. has 9 pending office actions as of October 2026, spread across 8 art units and 9 examiners.
Andrew S Rosenthal has the most, with 1 of Kowa Company, Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
